FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2119639423> ?p ?o ?g. }

• W2119639423 abstract "Antiprogestin compounds have been shown to be effective in blocking the growth of ovarian cancer cells of different genetic backgrounds. Herein we studied the anti-ovarian cancer effect of a series of antiprogestins sharing the chemical backbone of the most characterized antiprogestin, mifepristone, but with unique modifications in position C-17 of the steroid ring. We assessed the effect of mifepristone-like antiprogestins on the growth of ovarian cancer cells sensitive to the standard combination therapy cisplatin-paclitaxel or made double-resistant upon six cycles of pulse-selection with the drugs used at clinically relevant concentrations and exposure times. IGROV-1 and SKOV-3 cells were pulsed with 20 μM cisplatin for 1 h followed by 100 nM paclitaxel for 3 h once a week for six weeks. The cells that did not die and repopulate the culture after the chemotherapies were termed Platinum-Taxane-EScape cells (PTES). Parental cells were compared against their PTES derivatives in their responses to further platinum-taxane treatments. Moreover, both ovarian cancer cells and their PTES siblings were exposed to escalating doses of the various antiprogestin derivatives. We assessed cell growth, viability and sub-G1 DNA content using microcapillary cytometry. Cyclin-dependent kinase inhibitors p21cip1 and p27kip1 and cleavage of downstream caspase-3 substrate PARP were used to assess whether cell fate, as a consequence of treatment, was limited to cytostasis or progressed to lethality. Cells subjected to six pulse-selection cycles of cisplatin-paclitaxel gave rise to sibling derivatives that displayed ~2-7 fold reduction in their sensitivities to further chemotherapy. However, regardless of the sensitivity the cells developed to the combination cisplatin-paclitaxel, they displayed similar sensitivity to the antiprogestins, which blocked their growth in a dose-related manner, with lower concentrations causing cytostasis, and higher concentrations causing lethality. Antiprogestins carrying a backbone similar to mifepristone are cytotoxic to ovarian cancer cells in a manner that does not depend on the sensitivity the cells have to the standard ovarian cancer chemotherapeutics, cisplatin and paclitaxel. Thus, antiprogestin therapy could be used to treat ovarian cancer cells showing resistance to both platinum and taxanes." @default.
• W2119639423 created "2016-06-24" @default.
• W2119639423 creator A5004596792 @default.
• W2119639423 creator A5011048772 @default.
• W2119639423 creator A5046034293 @default.
• W2119639423 creator A5090973571 @default.
• W2119639423 date "2014-04-27" @default.
• W2119639423 modified "2023-10-15" @default.
• W2119639423 title "Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity" @default.
• W2119639423 cites W1546988495 @default.
• W2119639423 cites W1922735013 @default.
• W2119639423 cites W1974756790 @default.
• W2119639423 cites W1981694233 @default.
• W2119639423 cites W1984901643 @default.
• W2119639423 cites W2006745156 @default.
• W2119639423 cites W2009298354 @default.
• W2119639423 cites W2011069301 @default.
• W2119639423 cites W2012733679 @default.
• W2119639423 cites W2034836489 @default.
• W2119639423 cites W2045180596 @default.
• W2119639423 cites W2050671819 @default.
• W2119639423 cites W2058701056 @default.
• W2119639423 cites W2062006818 @default.
• W2119639423 cites W2062908963 @default.
• W2119639423 cites W2068854353 @default.
• W2119639423 cites W2075711878 @default.
• W2119639423 cites W2089492674 @default.
• W2119639423 cites W2090968329 @default.
• W2119639423 cites W2091928856 @default.
• W2119639423 cites W2103816214 @default.
• W2119639423 cites W2111150600 @default.
• W2119639423 cites W2126087169 @default.
• W2119639423 cites W2126280475 @default.
• W2119639423 cites W2126753591 @default.
• W2119639423 cites W2126985539 @default.
• W2119639423 cites W2127048228 @default.
• W2119639423 cites W2143578597 @default.
• W2119639423 cites W2153835789 @default.
• W2119639423 cites W2159309145 @default.
• W2119639423 doi "https://doi.org/10.1186/1757-2215-7-45" @default.
• W2119639423 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4007005" @default.
• W2119639423 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24795781" @default.
• W2119639423 hasPublicationYear "2014" @default.
• W2119639423 type Work @default.
• W2119639423 sameAs 2119639423 @default.
• W2119639423 citedByCount "20" @default.
• W2119639423 countsByYear W21196394232014 @default.
• W2119639423 countsByYear W21196394232015 @default.
• W2119639423 countsByYear W21196394232016 @default.
• W2119639423 countsByYear W21196394232017 @default.
• W2119639423 countsByYear W21196394232018 @default.
• W2119639423 countsByYear W21196394232019 @default.
• W2119639423 countsByYear W21196394232020 @default.
• W2119639423 countsByYear W21196394232021 @default.
• W2119639423 countsByYear W21196394232022 @default.
• W2119639423 crossrefType "journal-article" @default.
• W2119639423 hasAuthorship W2119639423A5004596792 @default.
• W2119639423 hasAuthorship W2119639423A5011048772 @default.
• W2119639423 hasAuthorship W2119639423A5046034293 @default.
• W2119639423 hasAuthorship W2119639423A5090973571 @default.
• W2119639423 hasBestOaLocation W21196394231 @default.
• W2119639423 hasConcept C109316439 @default.
• W2119639423 hasConcept C121608353 @default.
• W2119639423 hasConcept C126322002 @default.
• W2119639423 hasConcept C143998085 @default.
• W2119639423 hasConcept C185592680 @default.
• W2119639423 hasConcept C202751555 @default.
• W2119639423 hasConcept C2776694085 @default.
• W2119639423 hasConcept C2777292972 @default.
• W2119639423 hasConcept C2777511904 @default.
• W2119639423 hasConcept C2778239845 @default.
• W2119639423 hasConcept C2778826759 @default.
• W2119639423 hasConcept C2779234561 @default.
• W2119639423 hasConcept C2780427987 @default.
• W2119639423 hasConcept C502942594 @default.
• W2119639423 hasConcept C530470458 @default.
• W2119639423 hasConcept C54355233 @default.
• W2119639423 hasConcept C55493867 @default.
• W2119639423 hasConcept C62112901 @default.
• W2119639423 hasConcept C71924100 @default.
• W2119639423 hasConcept C86803240 @default.
• W2119639423 hasConcept C96232424 @default.
• W2119639423 hasConcept C98274493 @default.
• W2119639423 hasConceptScore W2119639423C109316439 @default.
• W2119639423 hasConceptScore W2119639423C121608353 @default.
• W2119639423 hasConceptScore W2119639423C126322002 @default.
• W2119639423 hasConceptScore W2119639423C143998085 @default.
• W2119639423 hasConceptScore W2119639423C185592680 @default.
• W2119639423 hasConceptScore W2119639423C202751555 @default.
• W2119639423 hasConceptScore W2119639423C2776694085 @default.
• W2119639423 hasConceptScore W2119639423C2777292972 @default.
• W2119639423 hasConceptScore W2119639423C2777511904 @default.
• W2119639423 hasConceptScore W2119639423C2778239845 @default.
• W2119639423 hasConceptScore W2119639423C2778826759 @default.
• W2119639423 hasConceptScore W2119639423C2779234561 @default.
• W2119639423 hasConceptScore W2119639423C2780427987 @default.
• W2119639423 hasConceptScore W2119639423C502942594 @default.
• W2119639423 hasConceptScore W2119639423C530470458 @default.
• W2119639423 hasConceptScore W2119639423C54355233 @default.
• W2119639423 hasConceptScore W2119639423C55493867 @default.

• next